↓ Skip to main content

Preclinical analysis of the anti-tumor and anti-metastatic effects of Raf265 on colon cancer cells and CD26+ cancer stem cells in colorectal carcinoma

Overview of attention for article published in Molecular Cancer, April 2015
Altmetric Badge

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
25 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Preclinical analysis of the anti-tumor and anti-metastatic effects of Raf265 on colon cancer cells and CD26+ cancer stem cells in colorectal carcinoma
Published in
Molecular Cancer, April 2015
DOI 10.1186/s12943-015-0352-y
Pubmed ID
Authors

Ariel KM Chow, Nathan SM Cheng, Colin SC Lam, Lui Ng, Sunny KM Wong, Timothy MH Wan, Johnny HW Man, Alvin HK Cheung, Thomas CC Yau, Jensen TC Poon, Wai-Lun Law, Roberta WC Pang

Abstract

In colorectal carcinoma (CRC), activation of the Raf/MEK/ERK signaling pathway is commonly observed. In addition, the commonly used 5FU-based chemotherapy in patients with metastatic CRC was found to enrich a subpopulation of CD26(+) cancer stem cells (CSCs). As activation of the Raf/MEK/ERK signaling pathway was also found in the CD26(+) CSCs and therefore, we hypothesized that an ATP-competitive pan-Raf inhibitor, Raf265, is effective in eliminating the cancer cells and the CD26(+) CSCs in CRC patients. HT29 and HCT116 cells were treated with various concentrations of Raf265 to study the anti-proliferative and apoptotic effects of Raf265. Anti-tumor effect was also demonstrated using a xenograft model. Cells were also treated with Raf265 in combination with 5FU to demonstrate the anti-migratory and invasive effects by targeting on the CD26(+) CSCs and the anti-metastatic effect of the combined treatment was shown in an orthotopic CRC model. Raf265 was found to be highly effective in inhibiting cell proliferation and tumor growth through the inhibition of the RAF/MEK/ERK signaling pathway. In addition, anti-migratory and invasive effect was found with Raf265 treatment in combination with 5FU by targeting on the CD26(+) cells. Finally, the anti-tumor and anti-metastatic effect of Raf265 in combination with 5FU was also demonstrated. This preclinical study demonstrates the anti-tumor and anti-metastatic activity of Raf265 in CRC, providing the basis for exploiting its potential use and combination therapy with 5FU in the clinical treatment of CRC.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Iran, Islamic Republic of 1 4%
Luxembourg 1 4%
Unknown 23 92%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 24%
Other 5 20%
Student > Ph. D. Student 5 20%
Student > Bachelor 3 12%
Student > Master 2 8%
Other 1 4%
Unknown 3 12%
Readers by discipline Count As %
Agricultural and Biological Sciences 7 28%
Biochemistry, Genetics and Molecular Biology 5 20%
Medicine and Dentistry 5 20%
Nursing and Health Professions 1 4%
Immunology and Microbiology 1 4%
Other 1 4%
Unknown 5 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 April 2015.
All research outputs
#3,560,918
of 5,035,251 outputs
Outputs from Molecular Cancer
#420
of 605 outputs
Outputs of similar age
#114,366
of 155,496 outputs
Outputs of similar age from Molecular Cancer
#29
of 35 outputs
Altmetric has tracked 5,035,251 research outputs across all sources so far. This one is in the 16th percentile – i.e., 16% of other outputs scored the same or lower than it.
So far Altmetric has tracked 605 research outputs from this source. They receive a mean Attention Score of 2.9. This one is in the 13th percentile – i.e., 13% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 155,496 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 35 others from the same source and published within six weeks on either side of this one. This one is in the 5th percentile – i.e., 5% of its contemporaries scored the same or lower than it.